Table 1 Clinical characteristics of included ReDLat participants
AD n = 999 | FTD n = 381 | MCI n = 8 | OTHER n = 19 | HC n = 755 | ||
|---|---|---|---|---|---|---|
Age < 65years, n (%) | 139 (13.9) | 85 (22.3) | 2 (25.0) | 2 (10.5) | 277 (36.7) | |
Female, n (%) | 665 (66.6) | 201 (52.8) | 6 (75.0) | 8 (42.1) | 516 (68.3) | |
AD phenotype, n (%) | Amnestic | 521 (52.2) | – | – | – | – |
lvPPA | 10 (1.0) | – | – | – | – | |
PCA | 6 (0.6) | – | – | – | – | |
fvAD | 1 (0.1) | – | – | – | – | |
usAD | 461 (46.1) | – | – | – | – | |
FTD phenotype, n (%) | bvFTD | – | 196 (51.4) | – | – | – |
nfPPA | – | 25 (6.6) | – | – | – | |
svPPA | – | 37 (9.7) | – | – | – | |
FTD-CBS | – | 26 (6.8) | – | – | – | |
FTD-MND | – | 9 (2.4) | – | – | – | |
FTD-PSP | – | 9 (2.4) | – | – | – | |
usFTD | – | 72 (18.9) | – | – | – | |
usPPA | – | 7 (1.8) | – | – | – | |
APOE ε4 carriers, n (%) | Heterozygous | 408 (41.5) | 96 (25.9) | 1 (14.3) | 2 (10.5) | 153 (20.7) |
Homozygous | 85 (8.6) | 15 (4.0) | – | 1 (5.3) | 13 (1.8) | |
Country of origin | Argentina | 191 (19.1) | 2 (0.5) | – | 1 (5.3) | 74 (9.8) |
Brazil | 42 (4.2) | 99 (26.0) | – | – | 88 (11.7) | |
Chile | 115 (11.5) | 45 (11.8) | 6 (75.0) | 11 (57.9) | 115 (15.2) | |
Colombia | 536 (53.7) | 193 (50.7) | 1 (12.5) | 6 (31.6) | 289 (38.3) | |
Mexico | 59 (5.9) | 17 (4.5) | – | – | 133 (17.6) | |
Peru | 56 (5.6) | 25 (6.6) | 1 (12.5) | 1 (5.3) | 56 (7.4) | |
Genomic data, n (%) | SNP Array | 282 (28.2) | 126 (33.1) | 6 (75.0) | 10 (52.6) | 234 (31.0) |
WES | 6 (0.6) | – | – | – | 3 (0.4) | |
WGS | 711 (71.2) | 255 (66.9) | 2 (25.0) | 9 (47.4) | 518 (68.6) | |
